Insmed, Inc. (INSM): Price and Financial Metrics


Insmed, Inc. (INSM): $19.27

0.09 (+0.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INSM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INSM POWR Grades


  • Growth is the dimension where INSM ranks best; there it ranks ahead of 63.48% of US stocks.
  • The strongest trend for INSM is in Growth, which has been heading up over the past 179 days.
  • INSM's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

INSM Stock Summary

  • With a price/sales ratio of 14.63, INSMED Inc has a higher such ratio than 90.22% of stocks in our set.
  • With a year-over-year growth in debt of 51.24%, INSMED Inc's debt growth rate surpasses 83.79% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for INSM comes in at -22.25% -- higher than that of only 16.87% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to INSMED Inc, a group of peers worth examining would be INFN, RDUS, KPTI, BYSI, and ALBO.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to www.insmed.com.

INSM Valuation Summary

  • In comparison to the median Healthcare stock, INSM's EV/EBIT ratio is 129.01% lower, now standing at -8.5.
  • Over the past 243 months, INSM's price/sales ratio has gone down 880.4.
  • Over the past 243 months, INSM's price/sales ratio has gone down 880.4.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2021-08-31 18.9 6.1 -8.6 -8.5
INSM 2021-08-30 18.7 6.0 -8.5 -8.4
INSM 2021-08-27 18.2 5.8 -8.3 -8.1
INSM 2021-08-26 17.4 5.6 -7.9 -7.8
INSM 2021-08-25 17.7 5.7 -8.1 -7.9
INSM 2021-08-24 17.2 5.5 -7.8 -7.6

INSM Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 66.18%.
  • Its 4 year net cashflow from operations growth rate is now at -122.83%.
  • The year over year price growth rate now stands at 41.3%.
INSM's revenue has moved up $19,755,000 over the prior 15 months.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 188.461 -363.302 -434.654
2021-09-30 173.752 -345.962 -423.889
2021-06-30 170.638 -329.185 -374.834
2021-03-31 167.767 -289.694 -319.367
2020-12-31 164.413 -219.348 -294.09
2020-09-30 168.706 -196.96 -244.865

INSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INSM has a Quality Grade of C, ranking ahead of 31.6% of graded US stocks.
  • INSM's asset turnover comes in at 0.172 -- ranking 207th of 682 Pharmaceutical Products stocks.
  • CYRX, CTLT, and ACOR are the stocks whose asset turnover ratios are most correlated with INSM.

The table below shows INSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.172 0.760 -0.609
2021-06-30 0.192 0.753 -0.585
2021-03-31 0.209 0.754 -0.551
2020-12-31 0.206 0.757 -0.513
2020-09-30 0.215 0.776 -0.415
2020-06-30 0.214 0.795 -0.422

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.78 Average Broker Recommendation 1.4 (Strong Buy)

INSM Stock Price Chart Interactive Chart >

Price chart for INSM

INSM Price/Volume Stats

Current price $19.27 52-week high $34.44
Prev. close $19.18 52-week low $16.41
Day low $18.59 Volume 967,100
Day high $19.57 Avg. volume 1,043,432
50-day MA $22.33 Dividend yield N/A
200-day MA $25.30 Market Cap 2.30B

Insmed, Inc. (INSM) Company Bio


Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.


INSM Latest News Stream


Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream


Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED Inc that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Insmed: Temporarily Stuck

No summary available.

Seeking Alpha | February 19, 2022

Insmed Incorporated's (INSM) CEO Will Lewis on Q4 2021 Results - Earnings Call Transcript

Insmed Incorporated's (INSM) Q4 2021 Earnings Conference Call February 17, 2022, 8:00 AM ET Company Participants Will Lewis – Chairman and Chief Executive Officer Eleanor Barisser – Associate Director, Investor Relations Martina Flammer – Chief Medical Officer Roger Adsett – Chief Operating Officer Sara Bonstein – Chief Financial Officer Conference...

SA Transcripts on Seeking Alpha | February 17, 2022

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…

PR Newswire | February 17, 2022

Insmed Incorporated 2022 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 17, 2022

Insmed GAAP EPS of -$0.95 misses by $0.05, revenue of $56.12M beats by $5.28M

Insmed press release (INSM): Q4 GAAP EPS of -$0.95 misses by $0.05.Revenue of $56.12M (+35.5% Y/Y) beats by $5.28M.The company expects full-year 2022 revenues for ARIKAYCE to…

Seeking Alpha | February 17, 2022

Read More 'INSM' Stories Here

INSM Price Returns

1-mo -13.28%
3-mo -17.61%
6-mo -33.39%
1-year -21.22%
3-year -26.81%
5-year 19.91%
YTD -29.26%
2021 -18.17%
2020 39.41%
2019 82.01%
2018 -57.92%
2017 135.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7714 seconds.